Bio-Rad Laboratories (BIO) stock experienced a decline of 0.25%, attributed primarily to multiple brokerages lowering their price targets for the company, which may have influenced investor sentiment negatively.

Bio-Rad Laboratories (BIO) stock experienced a decline of 0

Bio-Rad Laboratories (BIO) stock rose by 0.97% due to recent institutional buying activity and a strong quarterly earnings report that exceeded analysts' expectations, despite some analysts lowering their target prices for the stock.

Bio-Rad Laboratories (BIO) stock rose by 0

Bio-Rad Laboratories (BIO) stock saw a slight decline of 0.04%, which may be attributed to broader market trends or investor sentiment surrounding biotechnology stocks, rather than specific negative developments related to the company itself.

Bio-Rad Laboratories (BIO) stock saw a slight decline of 0

Bio-Rad Laboratories (BIO) stock fell by 2.4% due to adjustments in price targets and ratings from several research firms, indicating a cautious outlook from analysts after a quarterly earnings report that showed a revenue decline despite beating earnings expectations.

Bio-Rad Laboratories (BIO) stock fell by 2

Bio-Rad Laboratories (BIO) stock declined by 2.4%, likely due to downward adjustments in price targets from major analysts and a reported revenue decrease compared to the previous year, despite exceeding earnings estimates.

Bio-Rad Laboratories (BIO) stock declined by 2

Bio-Rad Laboratories (BIO) stock fell by 1.12% due to various analysts downgrading their price targets following mixed quarterly earnings results and concerns about a year-over-year decline in revenue, despite beating earnings expectations.

Bio-Rad Laboratories (BIO) stock fell by 1

Bio-Rad Laboratories (BIO) stock rose by 2.69% due to increased institutional investor activity and positive earnings results that exceeded analyst expectations.

Bio-Rad Laboratories (BIO) stock rose by 2

Bio-Rad Laboratories (BIO) stock rose 0.36% as institutional investors made notable adjustments to their holdings, including both increases and decreases in stock ownership, while the company recently posted stronger-than-expected quarterly earnings, contributing to positive investor sentiment.

Bio-Rad Laboratories (BIO) stock rose 0

Bio-Rad Laboratories (BIO) stock fell by 1.09% primarily due to negative sentiment from analysts revising their price targets downward and changing ratings, which reflects concerns over the company's declining year-over-year revenue despite beating earnings expectations.

Bio-Rad Laboratories (BIO) stock fell by 1.09% likely due to market reactions to stock comparisons and analysis within the healthcare sector, particularly against small-cap companies like OncoCyte and Aclarion, which might have affected investor sentiment towards related stocks.

Bio-Rad Laboratories (BIO) stock rose 0.21% following a mix of institutional investment adjustments and positive earnings results that exceeded consensus estimates. The increase in stock price can be attributed to heightened investor interest, as evidenced by significant increases in holdings by several hedge funds, along with strong quarterly earnings that surpassed expectations by a considerable margin.

Bio-Rad Laboratories (BIO) stock decreased by 0.51% due to lowered price targets from several analysts and ratings cut, signaling reduced investor confidence despite a recent earnings beat.

Bio-Rad Laboratories (BIO) stock decreased by 0

Bio-Rad Laboratories (BIO) stock rose by 0.67% following a significant increase in institutional investment, including a 175.6% boost in holdings by Exchange Traded Concepts LLC, indicating growing confidence in the company's performance and recent earnings beat.

Bio-Rad Laboratories (BIO) stock decreased by 0.54% following a series of price target reductions from major financial institutions, indicating a less favorable outlook for the company's performance.

Bio-Rad Laboratories (BIO) stock rose by 2.11% last night, influenced by institutional investment activity, including Fifth Third Bancorp's reduced stake and other investors acquiring new stakes, as well as positive earnings results that exceeded analyst expectations.

Bio-Rad Laboratories (BIO) stock fell by 2.37% following a downgrade in their Q2 2025 EPS estimates by Zacks Research, which revised the forecast down from $2.14 to $2.03 per share, contributing to negative market sentiment around the stock.

Bio-Rad Laboratories (BIO) stock declined by 0.14% following a target price reduction from Wells Fargo & Company, which decreased its outlook for the stock from $260 to $245, amid a broader trend of downgrades by various analysts.

Bio-Rad Laboratories (BIO) stock declined by 0

Bio-Rad Laboratories (NYSE:BIO) saw a 2.2% increase in stock value, likely driven by positive quarterly earnings results that surpassed analyst expectations and increased interest from institutional investors who have been acquiring shares in significant numbers.

Bio-Rad Laboratories (NYSE:BIO) saw a 2

Bio-Rad Laboratories (BIO) stock rose by 2.8% due to increased investor interest, evidenced by significant stake growth from multiple institutional investors, despite several analysts lowering their price targets for the company.

Bio-Rad Laboratories' stock rose 2.8% despite being downgraded from a buy to a hold rating by Wall Street Zen, likely due to positive earnings results that exceeded consensus estimates and active support from institutional investors, as well as general market fluctuations.

Bio-Rad Laboratories' stock rose 2

Bio-Rad Laboratories (BIO) stock rose by 0.05% following significant institutional investments, with several firms increasing their positions in the company, indicating positive sentiment and confidence in its performance after reporting better-than-expected quarterly earnings.

Bio-Rad Laboratories (NYSE:BIO) shares fell by 1.23% amid several recent analyst downgrades that lowered price targets and ratings for the stock, despite a positive earnings report that exceeded expectations but reflected a decline in revenue compared to the previous year.

Bio-Rad Laboratories (NYSE:BIO) shares fell by 1

The article discusses the increase in the wealth of self-made women in America, highlighting the rising fortunes of various billionaires, including Alice Schwartz of Bio-Rad Laboratories, whose stock (BIO) saw a 1.85% increase likely due to investor confidence stemming from favorable market conditions or strong performance indicators within the biotech sector.

The article discusses the increase in the wealth of self-made women in America, highlighting the ris

Bio-Rad Laboratories (BIO) stock fell by 4.57% as the company's recent performance showed declining revenue of 4.2% year-over-year despite beating earnings expectations, leading to a mixed reaction from analysts and affecting investor sentiment.

Bio-Rad Laboratories (BIO) stock fell by 4

Bio-Rad Laboratories (BIO) experienced a 4.57% drop in stock value, likely influenced by a combination of decreased quarterly revenue compared to the previous year and recent price target reductions from various brokerages, despite exceeding earnings expectations.

Bio-Rad Laboratories (BIO) experienced a 4

Bio-Rad Laboratories (BIO) stock rose by 2.94% likely due to strong recent earnings performance, where the company exceeded revenue and earnings expectations, leading to increased institutional investment interest despite some analysts adjusting their price targets downward.

Bio-Rad Laboratories' stock (NYSE:BIO) declined by 1.48% following a downgrade in Q2 2025 earnings estimates by Zacks Research, lowering expectations from $2.91 to $2.14 per share, which negatively impacted investor confidence.

Bio-Rad Laboratories' stock (NYSE:BIO) declined by 1

Bio-Rad Laboratories (BIO) saw its stock rise by 3.64% due to stronger-than-expected earnings results and revenue that surpassed analysts’ predictions, signaling positive financial performance despite a slight decline in year-over-year revenue.

Bio-Rad Laboratories (BIO) saw its stock rise by 3

Bio-Rad Laboratories (NYSE:BIO) stock rose 1.63% after the company reported strong quarterly earnings, beating analysts' expectations, despite a recent target price decrease by Royal Bank of Canada and a negative outlook from some analysts.

Bio-Rad Laboratories (NYSE:BIO) stock rose 1

Bio-Rad Laboratories (BIO) stock dropped 1.7% after the company reported a quarterly earnings increase but a 4.2% decline in revenue year-over-year, which could indicate underlying issues despite beating EPS estimates.

Bio-Rad Laboratories (BIO) stock dropped 1

Bio-Rad Laboratories (BIO) stock rose by 0.9% likely due to positive investor sentiment stemming from its collaboration with OncoCyte, a company developing innovative diagnostic tests, indicating strong potential for ongoing growth and market performance.

Bio-Rad Laboratories (BIO) experienced a 0.9% increase in stock price, partly due to positive analyst ratings and its strategic acquisition of Stilla Technologies, which aims to enhance its product portfolio and digital PCR capabilities despite some recent financial softness and planned workforce reductions.

Bio-Rad Laboratories (BIO) experienced a 0

Bio-Rad Laboratories (BIO) stock increased by 3.42% due to a positive outlook on the company's solid financial profile despite recent challenges indicated in investment management reports. The stock's rise may reflect investor confidence in its recurring revenue potential and operating margin improvements, even amid a difficult funding environment.

Bio-Rad Laboratories (BIO) stock increased by 3

Bio-Rad Laboratories (BIO) stock rose by 3.42% due to recent trading activity among institutional investors, including significant increases in stakes by Venturi Wealth Management and other firms, indicating positive investor sentiment despite mixed analyst ratings.

Bio-Rad Laboratories (BIO) stock rose by 3

Bio-Rad Laboratories (BIO) stock fell by 0.55% due to institutional selling, particularly a 3.7% reduction in stake by Barclays PLC and mixed ratings and target price adjustments from analysts, which may have influenced investor sentiment.

Bio-Rad Laboratories (BIO) stock fell by 0

Bio-Rad Laboratories (BIO) stock fell by -0.55% due to a combination of government funding cuts and disappointing quarterly results, despite a belief in its long-term growth potential.

Bio-Rad Laboratories (BIO) stock fell by -0

Bio-Rad Laboratories' (BIO) stock rose 0.09% following a series of institutional investments and changes in hedge fund positions, indicating continued interest and support from the investment community despite mixed ratings from research firms.

Bio-Rad Laboratories' (BIO) stock rose 0

Bio-Rad Laboratories (BIO) stock rose by 0.09% due to changes in institutional investor holdings, including significant increases by firms like Venturi Wealth Management, indicating growing interest and confidence in the company despite some mixed analyst ratings and adjustments to price targets.

Bio-Rad Laboratories (BIO) stock fell by 1.86% due to a significant reduction in stakes by Wellington Management Group, which sold 91.9% of its shares, reflecting a broader trend of institutional investors adjusting their holdings in the company.

Bio-Rad Laboratories (BIO) stock rose 1.68% as institutional investors, including the California Public Employees Retirement System, increased their stakes in the company, reflecting growing confidence in its growth potential and recent strong earnings performance.

Bio-Rad Laboratories (BIO) stock rose 1

Bio-Rad Laboratories (BIO) stock dropped by 1.46% following a significant decrease in holdings by Mitsubishi UFJ Trust & Banking Corp, along with mixed performances in analyst ratings and target price adjustments.

Bio-Rad Laboratories (BIO) stock dropped by 1

Bio-Rad Laboratories (BIO) stock fell by 1.68% as it dropped below its 200-day moving average, trading at $265.82, which may reflect concerns about its financial performance, including a negative net margin and a low price-to-earnings ratio.

Bio-Rad Laboratories (BIO) stock fell by 1.68%, likely influenced by Corient Private Wealth LLC reducing its holdings by 17% and a recent downgrade of its ratings by Wells Fargo and StockNews.com, indicating a decrease in investor confidence.

Bio-Rad Laboratories (BIO) stock decreased by 3.64% following CIBC World Markets Corp's decision to reduce its stake in the company by 24.5%, along with adjustments in positions by other institutional investors and analysts lowering their ratings and price targets for the stock.

Bio-Rad Laboratories (BIO) stock decreased by 3

Bio-Rad Laboratories (BIO) stock recently fell by 0.01%, potentially due to broader market trends or investor reactions to developments related to their business performance or financial metrics.

Bio-Rad Laboratories (BIO) stock recently fell by 0

Bio-Rad Laboratories (BIO) stock was down by 0.01% due to market volatility, but OncoCyte Corporation's ongoing development and future commercialization plans for a transplant rejection monitoring test are generating excitement, potentially offsetting negative market sentiments.

Bio-Rad Laboratories (BIO) stock was down by 0

Bio-Rad Laboratories (BIO) stock rose by 3.85% due to positive investor sentiment following the company reporting better-than-expected quarterly earnings and continued interest from institutional investors, despite some analysts lowering their target prices.

Bio-Rad Laboratories (BIO) stock fell by 2.44% likely due to a reduction in target prices by multiple research analysts, including Wells Fargo lowering it from $360 to $345, alongside other institutional investors adjusting their positions in the company.

Bio-Rad Laboratories' stock (BIO) rose by 1.31% despite a downgrade in Q1 2025 EPS estimates by Zacks Research and mixed ratings from analysts due to positive quarterly earnings that exceeded expectations and ongoing investor interest in the company's life science and clinical diagnostic products.

Bio-Rad Laboratories' stock (BIO) rose by 1

Bio-Rad Laboratories (BIO) stock dropped by 3.82% due to general market volatility impacting healthcare stocks, as highlighted in a comparison between Biodesix and First Choice Healthcare Solutions, where Biodesix exhibited stronger growth potential, which may have diverted investor interest away from Bio-Rad.

Bio-Rad Laboratories (BIO) stock dropped by 3

Bio-Rad Laboratories (BIO) stock decreased by 0.42% due to a combination of lowered price targets from analysts, which may reflect concerns about the company's recent financial performance and outlook in the market.

BIO

Latest News & Analysis